These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34775119)

  • 1. Pediatric eosinophilic bronchiolitis successfully treated with mepolizumab.
    Arceri T; Kurland G; Reyes-Múgica M; Larkin A
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):874-875. PubMed ID: 34775119
    [No Abstract]   [Full Text] [Related]  

  • 2. Eosinophilic bronchiolitis successfully treated with mepolizumab.
    Takeshita Y; Nobuyama S; Kanetsuna Y; Tanaka A; Adachi M; Sato T; Tada Y
    J Allergy Clin Immunol Pract; 2020 Mar; 8(3):1159-1161.e1. PubMed ID: 31678294
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.
    Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H
    J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.
    To M; Kono Y; Yamawaki S; Soeda S; Katsube O; Kishi H; To Y
    J Allergy Clin Immunol Pract; 2018; 6(5):1746-1748.e1. PubMed ID: 30201098
    [No Abstract]   [Full Text] [Related]  

  • 5. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
    Cormier M; Chaboillez S; Lemiere C
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
    García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
    Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
    J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
    Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.
    Pavord ID; Menzies-Gow A; Buhl R; Chanez P; Dransfield M; Lugogo N; Keene ON; Bradford ES; Yancey SW
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1121-1132.e7. PubMed ID: 32889223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.
    Moran AM; Ramakrishnan S; Borg CA; Connolly CM; Couillard S; Mwasuku CM; Pavord ID; Hinks TSC; Lehtimӓki L
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1314-1316. PubMed ID: 32584603
    [No Abstract]   [Full Text] [Related]  

  • 14. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 16. Mepolizumab for Eosinophilic COPD.
    Xia Y; Li W; Shen H
    N Engl J Med; 2018 Feb; 378(7):680-1. PubMed ID: 29446291
    [No Abstract]   [Full Text] [Related]  

  • 17. Mepolizumab for Eosinophilic COPD.
    Shahlavi‑Monavvar P; Mobasher-Jannat A
    N Engl J Med; 2018 Feb; 378(7):681. PubMed ID: 29446292
    [No Abstract]   [Full Text] [Related]  

  • 18. Mepolizumab for Eosinophilic COPD.
    Sciurba FC; Bradford ES; Pavord ID
    N Engl J Med; 2018 Feb; 378(7):681-683. PubMed ID: 29443666
    [No Abstract]   [Full Text] [Related]  

  • 19. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
    Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
    Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.